Xylem’s Q4 Beat Is Less About the Penny and More About a Backlog-to-Margin Conversion the Street Is Still Discounting

The print says Xylem is not getting paid enough for the quality of its backlog conversion. What was priced in was modest upside: consensus already sat near the company’s run-rate with Q4 revenue estimated at $2,371.7 million and EPS estimated at $1.41. What actually surprised was not the scale of the headline beat, with revenue actual at $2,397.0 million for a +1.1% surprise and EPS actual at $1.42 for a +0.7% surprise, but the combination of a +5.7% sequential revenue step, 38.9% gross margin, and guidance for full-year EBITDA margin expansion despite Q1 reported revenue growth of only 1% to 2%. The variant perception is that investors focused on the flat organic Q1 setup are missing the second leg of the story: Xylem’s value creation in 2026 is more likely to come from pricing, productivity, and mix than from a revenue acceleration. That matters because the company has already shown it can hold gross margin at 38.9% in both Q3 FY2025 and Q4 FY2025 while revenue moved from $2,268.0 million to $2,397.0 million, and management is now guiding EBITDA margin to expand another 70 to 110 basis points versus the prior year.

The financial trajectory supports that interpretation because the Q4 revenue beat landed after three quarters of choppy but positive growth rather than after a clean demand surge. Revenue moved from $2,069.0 million in Q1 FY2025 to $2,301.0 million in Q2 FY2025, then to $2,268.0 million in Q3 FY2025, and finally to $2,397.0 million in Q4 FY2025. That pattern matters because the year’s best gross margin, 38.9%, was achieved in both Q3 FY2025 and Q4 FY2025, not only in the highest-volume quarter. The market may be anchoring on the fact that Q1 FY2026 revenue in the history table is $2,125.0 million with 37.8% gross margin and $0.79 diluted EPS, but the Q4 call’s guidance framework is explicitly for a softer first quarter followed by sequential margin improvement. The company’s own Q4 accounts also frame the earnings power differently from the street-comparison basis: Bill Grogan said, “We also achieved a record quarterly EPS of $1.42, a 20% increase over the prior year.” The wording matters because management chose the record EPS and prior-year increase as the headline, while the street only got a penny of upside versus $1.41.

The revenue chart is useful because it shows why this is not a simple growth beat: Q4 FY2025 revenue of $2,397.0 million is the highest point in the quarterly history, but gross margin at 38.9% is the same as Q3 FY2025 and above every prior quarter in the table except no higher quarter exists in the data pack. The step from Q4 FY2024 revenue of $2,256.0 million and 38.0% gross margin to Q4 FY2025 revenue of $2,397.0 million and 38.9% gross margin shows that Xylem is expanding margin through the cycle rather than merely absorbing fixed cost in a single quarter. EPS did not fully mirror the margin story on the reported diluted EPS line, with diluted EPS at $1.37 in Q4 FY2025 versus $1.34 in Q4 FY2024, while management cited $1.42 on its own reported basis. That difference should not be collapsed into one number. The table basis gives the sequential and year-over-year pattern, and the call basis gives management’s own earnings framing. Both point the same way on direction, but they are not the same reporting basis.

The backlog and orders commentary is the clearest reason to look past a muted Q1 revenue guide. Grogan’s shortest sentence carried the most important balance-sheet signal: “With our backlog finishing at $4.6 billion.” A $4.6 billion backlog against Q4 revenue of $2,397.0 million is not just an order-book comfort blanket; it gives management a visible pool from which to convert margin-accretive projects while it walks away from lower-return revenue. Orders were up 7% in the quarter, which is enough to avoid the bear case that Q4 revenue was a pull-forward. More important, measurement and control solutions had backlog finishing the year roughly $1.4 billion, and orders in that area were up 22% driven by smart metering demand across water and energy. The market may be over-discounting Q1 flat organic growth because it is treating backlog as a timing buffer, while the company is describing it as a conversion asset tied to the higher-margin mix that supports the 2026 margin guide.

The segment detail also explains why China weakness is not the dominant read-through. Management said revenue was flat in one cited area, with double-digit growth in the US offset by an almost 30% decline in China. That is not a clean global water demand story, and it should prevent investors from overpaying for a broad macro recovery. But the same discussion points to MCS backlog finishing at roughly $1.4 billion and a segment supported by a $1.4 billion backlog across all businesses, with EBITDA margin of 20.2% that was 310 basis points higher than prior year. The tension is real: China’s almost 30% decline is a material drag, while US growth and smart metering orders up 22% are supporting backlog and margin. The right conclusion is not that demand is universally better; it is that the mix of demand Xylem is choosing to convert is better than the aggregate revenue line implies. That is the variant perception: this print should be valued more as a self-help and mix print than as a water capex acceleration print.

The guidance math reinforces that distinction because management is not asking investors to underwrite a heroic top line. For 2026, Grogan guided revenue of $9.1 billion to $9.2 billion, revenue growth of one to 3%, and organic revenue growth of two to 4%. Against that, EBITDA margin is expected to be 22.9 to, with the sentence in the transcript cutting off after “22.9 to,” and representing 70 to 110 basis points of expansion versus the prior year. The incomplete margin range is a data-quality limitation, but the expansion range is explicit. EPS is guided to $5.35 to $5.60. The market’s likely mistake is to treat one to 3% revenue growth as an industrial multiple cap, when the company is telling investors that productivity, volume, and price can offset inflation and still deliver 70 to 110 basis points of EBITDA margin expansion. If Xylem hits that framework on only two to 4% organic revenue growth, the stock should be judged on margin durability and capital deployment discipline rather than on whether reported growth clears mid-single digits.

The first-quarter guide is the bear case’s best evidence, but it is also the setup for the next inflection. Grogan said, “Drilling down on the first quarter, we anticipate reported revenue growth will be in the 1% to 2% range on a reported basis and flat organically.” That sentence deserves a quote because it is the clearest admission that near-term organic growth is not carrying the story. Management also expects first quarter EBITDA margin to be approximately 20.5% to 21% and first quarter EPS of $1.06 to $1.11. The comparison to Q4 FY2025 is optically difficult: Q4 revenue was $2,397.0 million, gross margin was 38.9%, and diluted EPS was $1.37 on the table basis, while Q1 FY2026 in the history table shows revenue of $2,125.0 million, gross margin of 37.8%, and diluted EPS of $0.79. The thesis is not that Q1 will look clean. The thesis is that investors should use Q1 to test whether the sequential improvement promised after the first quarter is visible in margin, not whether flat organic growth suddenly becomes acceleration.

The call delivery supports a more constructive read than the headline sentiment score alone, but it also warns that management was more measured on guidance than in Q3. The tone history shows Q1 FY2026 sentiment at 0.26, up +0.07 from Q4 FY2025, while guidance_tone fell to 0.32, down -0.09. That mix is not promotional: overall tone recovered, but management’s forward guidance language became more cautious. The important change is in the risk markers. Uncertainty fell by -21.1 to 53.0, and qa_evasiveness fell by -41.1 to 6.8, while tone_confidence rose by +0.12 to 0.40. In other words, the company sounded less evasive and less uncertain even as it guided Q1 organic revenue flat. AI optimism jumped by +0.79 to 0.90, but that should be weighted carefully because the same table shows guidance_tone at only 0.32. The best interpretation is that management has more conviction in specific productivity and technology opportunities than in a broad near-term revenue acceleration.

That tone profile also explains why the AI and data-center comments should be treated as option value, not the core model. Matthew Pine cited a broader demand backdrop when he said, “There were a lot of talk of pilot projects now scaling into productivity solutions and you know, that's why a lot of the AI, build out is racing ahead Actually, Gartner had a a recent prediction that 2026 hyperscalers would invest over $2 trillion in new data centers.” The quote matters because it shows why ai_optimism rose to 0.90, but the number is external color, not Xylem guidance. The investable semiconductor read-through is narrower and more concrete: Intel, identified as a customer for ultrapure water treatment systems, sits in the part of the value chain where water intensity, wastewater treatment, and zero liquid discharge matter. Pine also gave a customer proof point outside the named Intel relationship, noting that one aerospace customer is avoiding more than $30 million in wastewater disposal costs with zero liquid discharge technology. For Intel, the implication is not that Xylem quantified a new order; it did not. The implication is that Xylem’s MCS backlog of roughly $1.4 billion, orders up 22% in smart metering demand across water and energy, and full company backlog of $4.6 billion support continued availability of water infrastructure solutions for fab-adjacent and industrial water projects. The absence of named suppliers in the data pack means there is no defensible supplier read-through to make.

The peer comparison matters because Xylem’s margin profile screens closer to the high-quality end of fab subsystems than its revenue growth rate suggests. In the latest reported quarter, peer revenue YoY ranged from -8.3% at 1979.T to +17.6% at 6856.T, while gross margin ranged from 14.3% at 1812.T to 43.8% at 6856.T. Xylem’s Q4 FY2025 revenue YoY was +6.2% and gross margin was 38.9%. That places Xylem’s growth above 1812.T at +4.0%, 7012.T at +3.9%, 6383.T at 0.0%, 6370.T at -8.1%, 1979.T at -8.3%, 6622.T at +5.3%, and 6368.T at +4.9%, while below 6856.T at +17.6%. On margin, Xylem’s 38.9% matches 6368.T at 38.9%, trails 6370.T at 40.0% and 6856.T at 43.8%, and sits above 1812.T at 14.3%, 7012.T at 20.5%, 6383.T at 23.2%, 1979.T at 19.8%, and 6622.T at 24.5%. The comparative point is simple: investors do not need to assign Xylem a hypergrowth multiple to recognize that its gross margin and revenue growth combination is competitive within the fab-subsystems-adjacent set represented in the data pack.

Capital deployment is the other lever that can either validate or dilute the thesis. Pine said Xylem deployed about $250 million of capital toward M and A in the second half of the year and has “much more than that” already in process for 2026, while also saying the company will continue to target around $1 billion a year of capital deployment toward M and A. The numbers are large enough to matter relative to a business guiding 2026 revenue of $9.1 billion to $9.2 billion, but the bar should be high because management also discussed a $250 million business at less than 10% EBITDA margin and walk-away revenues tied to less profitable businesses. That is the internal capital-allocation tension: Xylem is asking investors to reward margin expansion and simplification while also putting material dollars to work in M and A. The thesis survives if acquisitions reinforce the same mix and productivity path that drove 38.9% gross margin in Q4 FY2025 and supports 70 to 110 basis points of EBITDA margin expansion. It weakens if the company buys revenue that resembles the $250 million business at less than 10% EBITDA margin without a clear path to the 20% range discussed for transitional factors.

What to watch next is specific. First, Q1 should confirm the revenue guide of 1% to 2% reported growth and flat organic growth, but the more important test is whether EBITDA margin lands in the approximately 20.5% to 21% range and whether management repeats that margins should be back up in the 20% range in the first quarter and then sequentially improve. Second, backlog should stay close enough to the $4.6 billion year-end level, and MCS backlog should remain anchored near roughly $1.4 billion, to support the conversion thesis; a visible break there would make Q4 look like a harvest quarter rather than a base. Third, orders need to sustain evidence of demand beyond the 7% quarterly increase, with smart metering compared against the 22% order growth cited for water and energy. Fourth, full-year guide integrity matters: revenue of $9.1 billion to $9.2 billion, organic revenue growth of two to 4%, EBITDA margin expansion of 70 to 110 basis points, and EPS of $5.35 to $5.60 are the confirmation levels. If Q1 shows flat organic growth but holds the margin range and backlog conversion language, the market is mispricing the print by focusing on growth deceleration. If Q1 misses the 20.5% to 21% EBITDA margin range or management backs away from 70 to 110 basis points of expansion, the margin-led thesis breaks.